مطالعه بافت‌‌شناسی آنژیوژنز درمانی به روش مهندسی بافت در رت: نقش ماست‌سل‌ها و پلاکت‌‌ها در القاء آنژیوژنز

نویسندگان
علی کریمی
رسول شهروز
رحیم حب نقی
رحیم محمدی
اسماعیل مرتاض
فرهاد سلطانعلی نژاد
غلامرضا نجفی
سعیده امانی
چکیده
مقدمه

بیماری‌‌های عروق محیطی در اثر قطع جریان خون در اندام‌‌ها ایجاد می‌‌شود. ماست‌‌سل‌‌ها و‌‌ پلاکت‌‌ها با القاء آنژیوژنز و افزایش رگ‌‌زایی ممکن است موجب تسریع در بهبود شرایط ایسکمی موضعی شوند. هدف از مطالعه حاضر کمک به پیدا کردن روش درمانی مؤثر برای بهبود شرایط ایسکمی موضعی، در محل قطع شریان رانی می‌‌باشد.

مواد و روش‌‌ها

۳۰ قطعه رت نر سفید نژاد Wistar به ۶ گروه آزمایشی که همگی شامل حیوانات دچار ایسکمی بودند بطور تصادفی تقسیم شدند (۵=n): گروه کنترل ایسکمی: برش در محل شریان رانی و برداشت به طول mm۵، گروه کنترل محلول فسفات بافر (PBS): به منطقه برش PBS اضافه گردید، گروه کنترل کیتوزان (CHIT): به منطقه برش محلول کیتوزان اضافه گردید‌‌. گروه تجربی پیوند ماست سل (CHIT/Mast cells): به منطقه برش محلول کیتوزان و ماست سل (۱۰۶×۱) اضافه شد. گروه تجربی پیوند پلاکت (CHIT/plat): به منطقه برش محلول کیتوزان و پلاکت (۱۰۶×۱۳) اضافه گردید. گروه تجربی پیوند پلاکت و ماستسل (CHIT/plat/Mast cells): به منطقه برش محلول کیتوزان، ۱۰۶×۱۳ پلاکت و ماست سل (۱۰۶×۱) اضافه شد.

یافته‌‌ها

آنالیز داده‌‌های مربوط به تراکم عروق و هیستومورفومتری روز ۷ بعد از جراحی صورت گرفت. میانگین تعداد عروق خونی در گروه CHIT/Mast افزایش معنی‌‌داری نسبت به سایر گروه‌‌های آزمایشی نشان داد (p<۰/۰۵). میانگین مربوط به تعداد عروق متوسط و بزرگ در گروه CHIT/Mast بطور مؤثری بیشتر از گروه‌‌های کنترل بود (p<۰/۰۵).

نتیجه‌‌گیری

استفاده از ماست‌‌سل‌‌ها در مهندسی بافت می‌‌تواند پیشنهادی با رویکرد جدید در راستای آنژیوژنز درمانی تلقی شود، که قادر به ارائه بهبود روند رگزایی در موارد ابتلا به بیماری‌‌های عروق محیطی باشد.
کلیدواژه‌ها
آنژیوژنز
ماست سل
مهندسی بافت
پلاکت
بافت‌‌شناسی

عنوان مقاله English

Histological Study of Therapeutic Angiogenesis in Rat by Tissue Engineering Method: Role of Bone Marrow Mast Cells and Platelets in Induction of Angiogenesis

نویسندگان English

Ali Karimi
Rasul Shahrooz
Rahim Hobbenaghi
Rahim Mohamadi
Esmaeil Mortaz
Farhad Soltanalinejad
Gholamreza Najafi
Saeedeh Amani
چکیده English

Introduction

Peripheral arterial disease is the result of obstruction of blood circulation. Mast cells and platelets via induction of angiogenesis may cause the enhancement of amelioration local ischemia. The aim of this study was help to find an appropriate approach to recovery of ischemic condition in the restricted femoral artery localization.

Materials and Methods

30 male white Wistar rats were divided into 6 ischemic experimental groups (n=5), randomly: Ischemia control group: the femoral artery was transected‚ Phosphate buffer control solution (PBS) group: the transected location was immersed with PBS, Chitosan control group (CHIT): the transected location was immersed with chitosan solution, Mast cell transplanted experimental group (CHIT/Mast cells): the transected location was immersed with chitosan and mast cells (1× 106). Platelets transplanted experimental group (CHIT/plat): the transected location was immersed with chitosan and platelets (13×106). Platelets and mast cells transplanted experimental group (CHIT/plat/Mast cells): the transected location was immersed with chitosan, 13×106 platelets and mast cells (1×106).

Results

Analyses of capillary density and histomorphometrical analysis were performed on day 7 after surgery. Mean number of blood vessels in CHIT/Mast cells group indicated a significant difference compared to other experimental groups (P<0.05). The mean number of medium and large blood vessels in CHIT/Mast cells group was significantly more than control groups (P<0.05).

Conclusion

Mast cells using in tissue engineering could offer a new approach for therapeutic angiogenesis which is able to provide improved neovascularization in cases of peripheral arterial diseases.

کلیدواژه‌ها English

Angiogenesis
Mast Cells
Tissue Engineering
Platelets
Histology
Heart and Stroke Statistical Update. Dallas: American Heart Association. 2007. Available from: URL: https://www.heart.org/HEARTORG /General/Heart-and-Stroke-Association-Statistics_UCM_319064_SubHomePage.jsp.
Hobo K, Shimizu T, Sekine H, Shin’oka T, Okano T, Kurosawa H. Therapeutic angiogenesis using tissue engineered human smooth muscle cell sheets. Arterioscler Thromb Vasc Biol 2008; 28(4):637-43.
Second European Consensus Document on Chronic Critical Leg Ischemia. Circulation 1991; 84(4 Suppl):IV1-26.
Wagoner LE, Merrill W, Jacobs J, Conway G, Boehmer J, Thomas K, et al. Angiogenesis protein therapy with human fibroblast growth factor (FGF-1): results of a phase I open label, dose escalation study in subjects with CAD not eligible for PCI or CABG. Circulation 2007; 116(16 Suppl):II-443.
Risau W. Mechanisms of angiogenesis. Nature 1997; 386(6626):671-4.
Hamano K, Nishida M, Hirata K, Mikamo A, Li TS, Harada M, et al. Local Implantation of Autologous Bone Marrow Cells for Therapeutic Angiogenesis in Patients With Ischemic Heart Disease. Clinical Trial and Preliminary Results. Jpn Circ J 2001; 65(9):845-7.
Taniyama Y, Morishita R, Aoki M, Nakagami H, Yamamoto K, Yamazaki K, et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther 2001; 8(3):181-9.
Levi-Schaffer F, Pe’er J. Mast cells and angiogenesis. Clin Exp Allergy 2001; 31(4):521-4.
Norrby K. Mast cells and angiogenesis. APMIS 2002; 110(5):355-71.
Xing D, Zhang R, Li S, Huang P, Luo C, Hei Z, et al. Pivotal role of mast cell carboxypeptidase A in mediating protection against small intestinal ischemia–reperfusion injury in rats after ischemic preconditioning. J Surg Res 2014; 192(1):177-86.
Shao Z, Nazari M, Guo L, Li SH, Sun J, Liu SM, et al. The cardiac repair benefits of inflammation do not persist: evidence from mast cell implantation. J Cell Mol Med 2015; 19(12):2751-62.
Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997; 77(4):1033-79.
Furcht LT. Critical factors controlling angiogenesis: cell products, cell matrix, and growth factors. Lab Invest 1986; 55(5):505-9.
Sabrkhany S, Griffioen AW, oudeEgbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011; 1815(2):189-96.
Nerem RM. Tissue engineering in the USA. Med Biol Eng Comput 1992; 30(4):CE8-12.
Lee-Brown RK, Laidley JW. Some observations on the microscopical anatomy of the kidney. J Urol 1929; 21:259-74.
Mortaz E, Redegeld FA, Nijkamp FP, Engels F. Dual effects of acetylsalicylic acid on mast cell degranulation, expression of cyclooxygenase-2 and release of pro-inflammatory cytokines. Biochem Pharmacol 2005; 69(7):1049-57.
Givi ME, Blokhuis BR, Da Silva CA, Adcock I, Garssen J, Folkerts G, et al. Cigarette Smoke Suppresses the Surface Expression of c-kit and FcεRI on Mast Cells. Mediators Inflamm 2013; 2013.
Messora MR, Nagata MJ, Furlaneto FA, Dornelles RC, Bomfim SR, Deliberador TM, et al. A standardized research protocol for platelet-rich plasma (PRP) preparation in rats. RSBO 2011; 8(3):299-304.
Ojagh SM, Rezaei M, Razavi SH, Hosseini SM. Development and evaluation of a novel biodegradable film made from chitosan and cinnamon essential oil with low affinity toward water. Food Chem 2010; 122(1):161-6.
Isner JM, Walsh K, Symes J, Pieczek A, Takeshita S, Lowry J, et al. Arterial Gene Transfer for Therapeutic Angiogenesis in Patients with Peripheral Artery Disease. St. Elizabeth's Medical Center, Tufts University School of Medicine, Boston, Massachusetts. Human Gene Therapy 1996; 7(8):959-88.
Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M, et al. Gene therapy for myocardial angiogenesis initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98(25):2800-4.
Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204(3):322-30.
Ma L, Elliott SN, Cirino G, Buret A, Ignarro LJ, Wallace JL. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001; 98(11):6470-5.
Yamashiro K, Tsujikawa A, Ishida S, Usui T, Kaji Y, Honda Y, et al. Platelets accumulate in the diabetic retinal vasculature following endothelial death and suppress blood-retinal barrier breakdown. Am J Pathol 2003; 163(1):253-9.
Hiraizumi Y, Transfeldt EE, Kawahara N, Sung JH, Knighton D, Fiegeil VD. In vivo angiogenesis by platelet-derived wound-healing formula in injured spinal cord. Brain Res Bull 1993; 30(3-4):353-7.
Steed D, Goslen B, Hambley R, Abell E, Hebda P, Webster M. Clinical trials with purified platelet releasate. Prog Clin Biol Res 1990; 365:103-13.
Hiragun T, Morita E, Tanaka T, Kameyoshi Y, Yamamoto S. A fibrogenic cytokine, platelet-derived growth factor (PDGF), enhances mast cell growth indirectly via a SCF-and fibroblast-dependent pathway. J Invest Dermatol 1998; 111(2):213-7.
de Vries VC, Pino-Lagos K, Nowak EC, Bennett KA, Oliva C, Noelle RJ. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity 2011; 35(4):550-61.
Gan PY, Summers SA, Ooi JD, O’Sullivan KM, Tan DS, Muljadi RC, et al. Mast cells contribute to peripheral tolerance and attenuate autoimmune vasculitis. Clin J Am Soc Nephrol 2012; 23(12):1955-66.
Lu LF, Lind EF, Gondek DC, Bennett KA, Gleeson MW, Pino-Lagos K, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 2006; 442(7106):997-1002.